Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Geriatric Depression
NCT03833063Phase 1Withdrawn
- Sponsor
- Stavanger University Hospital
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Botulinum Toxin A with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 16 weeks. Planned start May 2019; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03833063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833063.